Adaptive Biotechnologies empowers revolutionary insights into the adaptive immune system that will change the course of medicine.
Adaptive is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. We bring the accuracy and sensitivity of our immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
Adaptive is committed to transforming the diagnosis and treatment of immune-mediated diseases including cancer, autoimmune disorders, and infectious disease through ground-breaking immunosequencing applications.
- Adaptive Biotechnologies illuminates the adaptive immune system through high-throughput bias-controlled sequencing of T- and B-cell receptors, and makes this sequencing data accessible through a proprietary data analysis and visualization platform.
- With constant dedication to discovery and ever-evolving product development, Adaptive empowers researchers and clinicians to discover the brilliance of the adaptive immune system.
- Adaptive Biotechnologies is on the forefront of creating and enabling revolutionary immune-based discoveries that will radically advance science and medicine worldwide.
It was in a cafeteria at Fred Hutchinson Cancer Research Center in Seattle, where Dr. Harlan Robins, Dr. Chris Carlson and Dr. Edus Warren were collaborating on a research project. Over lunch one day, they started asking questions related to isolating and amplifying T-cell receptors from the human genome when they had an “aha!” moment.
Shortly after, in 2009, Adaptive Biotechnologies was born. The brain-child of two brothers (Chad and Harlan Robins) with one mission - to change the course of medicine and improve patient care worldwide. Over the years Adaptive has successfully gained the interest of strong investors, academic organizations and customers who understand the importance of sequencing the immune system in order to revolutionize the way we discover, diagnose and treat diseases.
To further the momentum, in 2015, Adaptive acquired Sequenta, Inc., a South San Francisco-based company dedicated to improving patient care in diseases mediated by immune cells through the discovery and development of novel clinical diagnostics.
Now with over 200 employees, three locations, and products and services in both the research and diagnostics segments, Adaptive is not just the pioneer but also the leader in immunosequencing that will change the course of medicine worldwide.
Check out the lastest Adaptive News!
WE BELIEVE IN…
The power of sharing know-how
among the greater scientific
community to accelerate
Helping scientists realize their
discovery dreams, and using
our expertise to empower them.
The power of simplicity within
inherently complex science.
Our products and processes are
designed to streamline our
customers' workflow so they
have more time to pursue
interesting scientific questions.
Increasing access to the power of
to advance medical research.